Peter M. Hecht has served as our chief executive officer since our founding in 1998. Prior to founding Ironwood, Dr. Hecht was a research fellow at Whitehead Institute for Biomedical Research. Dr. Hecht earned a B.S. in mathematics and an M.S. in biology from Stanford University, and holds a Ph.D. in molecular biology from the University of California at Berkeley.
Brian Cali, an Ironwood founder, has served as our senior vice president of preclinical research and development since October 2010. Prior to this, he oversaw program management for seven years, helping to ensure effective leadership for our cross-functional research, development, and commercialization teams and alliances. Since Ironwood’s founding in 1998, Cali has held leadership positions in scientific management as well as business and organizational development. Prior to founding Ironwood, Cali was the Chiron fellow of the Life Sciences Research Foundation at Whitehead Institute for Biomedical Research. Cali earned a B.S. in microbiology from Cornell University and holds a Ph.D. in cellular and molecular biology from the University of Wisconsin–Madison.
Mark G. Currie serves as Ironwood’s senior vice president, chief scientific officer, and president of research and development. He has led the Company’s R&D efforts since joining Ironwood in 2002. Prior to joining Ironwood, he directed cardiovascular and central nervous system disease research as vice president of discovery research at Sepracor Inc. Previously, Dr. Currie initiated, built, and led discovery pharmacology and also served as director of arthritis and inflammation at Monsanto Company. Dr. Currie earned a B.S. in biology from the University of South Alabama and holds a Ph.D. in cell biology from the Bowman-Gray School of Medicine of Wake Forest University.
Jim DeTore joined Ironwood in 2003 and was appointed vice president of finance and administration in 2010. From 2006 until 2010, he served as our vice president of finance. From 2003 to 2006, DeTore served as our senior director of finance. Previously, DeTore held a variety of senior positions at Genzyme Corporation, including in the company's Renal and Pharmaceutical divisions where he managed worldwide financial operations. He also held management positions in manufacturing finance and corporate accounting. Earlier in his career he worked in corporate finance at Data General Corporation, a computer manufacturing company. DeTore earned both a B.S. and an M.B.A. from Northeastern University.
Legal Affairs & General Counsel
Halley Gilbert serves as Ironwood's vice president of legal affairs and general counsel. Prior to joining Ironwood in 2008, Ms. Gilbert was vice president and deputy general counsel of Cubist Pharmaceuticals, Inc. which she joined in 2002. Previously, Ms. Gilbert was corporate counsel of Genzyme Corporation. Ms. Gilbert started her legal career with Skadden, Arps, Slate, Meagher & Flom LLP, specializing in mergers and acquisitions and securities law. She received her J.D. from Northwestern University School of Law and a B.A. from Tufts University.
and Chief Financial Officer
Michael J. Higgins has served as our chief operating officer and chief financial officer since joining Ironwood in 2003. Prior to 2003, Mr. Higgins held a variety of senior business positions at Genzyme Corporation, including vice president of corporate finance. Mr. Higgins earned a B.S. from Cornell University and an M.B.A. from the Amos Tuck School of Business Administration at Dartmouth College.
Senior Vice President, Marketing & Sales
Thomas A. McCourt has served as Ironwood’s senior vice president of marketing and sales and chief commercial officer since joining the Company in September 2009. Prior to joining Ironwood, Mr. McCourt led the U.S. brand team for denosumab at Amgen Inc. from April 2008 to August 2009. Prior to that, he was with Novartis AG from 2001 to 2008, where he directed the launch and growth of Zelnorm for the treatment of patients with IBS-C and chronic constipation and held a number of senior commercial roles, including vice president of strategic marketing and operations. Mr. McCourt was also part of the founding team at Astra Merck Inc., leading the development of the medical affairs and science liaison group and then serving as brand manager for Prilosec. Mr. McCourt has a degree in pharmacy from the University of Wisconsin.
Todd Milne, an Ironwood founder, has provided scientific management leadership since Ironwood’s founding in 1998, and has been vice president of biology since October 2001. Previously, Milne was a fellow at Whitehead Institute for Biomedical Research. Milne’s research has earned him numerous awards and acknowledgements including fellowships from Merck and the Damon Runyon-Walter Winchell Cancer Research Fund. He earned a B.S. in molecular biophysics and biochemistry from Yale University and holds a Ph.D. in microbiology and molecular genetics from Harvard Medical School.
Jim O’Mara has served as Ironwood's vice president of corporate development since January 2006, and has been a leader in business development since joining the Company in October 2001. Prior to joining Ironwood, O’Mara was vice president of corporate development at Cozint Interactive, a healthcare marketing services company. He also served as a vice president for MPM Capital where he managed business development strategies and interactions for biotechnology and pharmaceutical companies. Earlier in his career, O’Mara held different sales and marketing positions at both Merck and Centocor. O’Mara earned a B.S. in pharmacy from the Massachusetts College of Pharmacy.